These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16767053)

  • 1. Diagnostic value of measuring serum CA 15-3, TPA, and TPS in women with breast cancer.
    Sliwowska I; Kopczyński Z; Grodecka-Gazdecka S
    Postepy Hig Med Dosw (Online); 2006; 60():295-9. PubMed ID: 16767053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of tissue polypeptide specific antigen TPS determination in serum of women with breast cancer comparison to mucin-like associated antigen MCA and CA 15-3 antigen.
    Kopczyński Z; Thielemann A
    Eur J Gynaecol Oncol; 1998; 19(5):503-7. PubMed ID: 9863926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of tissue polypeptide antigen (TPA) with cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in follow-up of breast cancer.
    Findeisen R; Albrecht S; Richter B; Deutschmann K; Distler W
    Clin Chem Lab Med; 1998 Nov; 36(11):841-6. PubMed ID: 9877089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of TPS and TPA in the Diagnostics of Distant Metastases.
    Kucera R; Topolcan O; Fiala O; Kinkorova J; Treska V; Zedníková I; Slouka D; Simanek V; Safanda M; Babuska V
    Anticancer Res; 2016 Feb; 36(2):773-7. PubMed ID: 26851038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer.
    D'Alessandro R; Roselli M; Ferroni P; Mariotti S; Spila A; Aloe S; Carone MD; Abbolito MR; Carlini S; Perri P; Ricciotti A; Botti C; Conti F; Vici P; Chiappetta NR; Cognetti F; Buonomo O; Guadagni F
    Breast Cancer Res Treat; 2001 Jul; 68(1):9-19. PubMed ID: 11678313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease.
    Bottini A; Berruti A; Tampellini M; Morrica B; Brunelli A; Gnocchi E; Brizzi MP; Aguggini S; Fara E; Alquati P; Dogliotti L
    Tumour Biol; 1997; 18(5):301-10. PubMed ID: 9276030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer.
    Sölétormos G; Petersen PH; Dombernowsky P
    Clin Chem Lab Med; 2000 May; 38(5):453-63. PubMed ID: 10952230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer.
    Kristiansen S; Jørgensen LM; Hansen MH; Nielsen D; Sölétormos G
    Biomed Res Int; 2015; 2015():986024. PubMed ID: 26339655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New mucin-like cancer-associated antigens (CA M 26, CA M 29 and CA 549) and a new proliferation marker (TPS) in patients with primary or advanced breast cancer.
    Locker GJ; Mader RM; Braun J; Sieder AE; Marosi C; Rainer H; Jakesz R; Steger GG
    Oncology; 1995; 52(2):140-4. PubMed ID: 7854774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis.
    Vizcarra E; Lluch A; Cibrián R; Jarque F; Alberola V; Belloch V; García-Conde J
    Breast Cancer Res Treat; 1996; 37(3):209-16. PubMed ID: 8825132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients.
    Schuurman JJ; Bong SB; Einarsson R
    Anticancer Res; 1996; 16(4B):2169-72. PubMed ID: 8694538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical study of serum tissue polypeptide-specific antigen in breast cancer].
    Zheng H; He BF; Luo RC; You CX; Mai GF; Lu HF
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Aug; 23(8):823-5. PubMed ID: 12919909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Serum concentration of selected neoplasm markers: CA15-3, TPS and CEA in women with diagnosed breast benign disease].
    Kochańska-Dziurowicz A; Pasich R; Stanjek A; Gaweł-Szostek V; Jankowski T
    Ginekol Pol; 2000 Sep; 71(9):1139-43. PubMed ID: 11082991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TPA and CA 15.3 measurements for breast cancer monitoring in a routine setting.
    Bonfrer JM; Korse CM
    Int J Biol Markers; 1999; 14(1):40-4. PubMed ID: 10367249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
    Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
    Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse.
    Vizcarra E; Lluch A; Cibrián R; Jarque F; García-Conde J
    Oncology; 1994; 51(6):491-6. PubMed ID: 7970492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
    Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
    Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
    Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
    Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.